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Recent studies have suggested that development of childhood acute lymphoblastic leukaemia may often be initiated in utero.
To provide further evidence of an prenatal origin of childhood leukaemia, we conducted a molecular biological investigation of
nine children with B-precursor acute lymphoblastic leukaemia carrying the chromosomal translocation t(12;21), the most
common subtype of all childhood acute lymphoblastic leukaemia. Speciﬁcally, for each child we identiﬁed the non-constitutive
chromosomal sequences made up by the t(12;21) fusion gene. From these, leukaemia clone-speciﬁc DNA primers were
constructed and applied in nested polymerase chain reaction analyses of DNA extracted from the patients’ Guthrie cards
obtained at birth. Leukaemia clone-speciﬁc fusion gene regions were demonstrated in Guthrie card DNA of three patients,
age 2 years 11 months, 3 years 4 months, and 5 years 8 months at leukaemia diagnosis. Our ﬁndings are consistent with
previous observations, and thus provide further evidence that the development of t(12;21) B-precursor acute lymphoblastic
leukaemia may be initiated in utero. Review of the current literature moreover indicates that age at leukaemia may be inversely
correlated with the burden of cells with leukaemia clonal markers, i.e. leukaemia predisposed cells at birth, and that certain
types of childhood acute lymphoblastic leukaemia develop as a multiple step process involving both pre- and postnatal genetic
events.
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Acute lymphoblastic leukaemia (ALL) is the most common of all
childhood cancers. It constitutes a group of different disease enti-
ties, which may be characterised by their epidemiology,
chromosomal, and molecular genetic aberrations besides by differ-
ences in clinical outcome (Greaves, 2002). Few risk factors for ALL
have been ﬁrmly established and consequently, until recently, little
was known about the time or age windows during which genetic
events critical to ALL development take place (Greaves, 2002).
However, within the last few years solid evidence has accumulated
that the ﬁrst or initiating genetic event in leukaemia development
often occurs in utero. Speciﬁcally, by analysing blood samples
obtained at birth in connection with routine screening for meta-
bolic conditions, it has been possible to demonstrate the
presence of leukaemia-clone-speciﬁc, non-constitutive chromoso-
mal translocations at birth in children diagnosed with leukaemia
at the age of several years (Gale et al, 1997; Wiemels et al,
1999a, 2002).
B-precursor ALL is the most common subtype of childhood
leukaemia, and accounts for the peak in ALL incidence seen
between the age of 2 and 5 years in the industrialised countries
(Greaves, 1999). Nearly 25% of all B-precursor ALL are charac-
terised by a translocation between chromosomes 12 and 21, i.e.
t(12;21) (Romana et al, 1995). This translocation fuses two puta-
tive transcriptional regulators, TEL and AML1, which are both
critical to the early haematopoiesis, producing a TEL-AML1 tran-
script (Rubnitz and Look, 1998). The preponderance and
homogeneity of t(12;21) B-precursor ALL make it a good model
to study the biology of childhood leukaemia. The literature being
limited to one previous study of nine singletons (Wiemels et al,
1999a), we therefore found it of interest to study the foetal origin
of t(12;21) B-precursor ALL by analysing peri-natally obtained
blood samples (Guthrie cards) for the presence of TEL-AML1
fusion genes in a series of patients diagnosed with this speciﬁc
leukaemia subtype.
MATERIALS AND METHODS
Patients and biological samples
In Denmark, neonatal screening for phenylketonuria and congeni-
tal myxedema through biochemical analysis of Guthrie cards has
been offered since 1980 (Simonsen et al, 1998). After analysis,
the Guthrie cards with residual blood spots are routinely stored
at Statens Serum Institut, Copenhagen. Taking advantage of this
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origin of childhood leukaemia. Using the population-based Danish
Cancer Registry (Storm et al, 1997), we identiﬁed all children diag-
nosed with ALL from January 1, 1996, until February 1999, in total
107 patients. Since 1996, reverse transcriptase polymerase chain
reactions (PCR) have routinely been performed on diagnostic
specimens for all children in Denmark diagnosed with ALL for
the presence of the most common genetic aberrations, including
t(12;21). We restricted the study population to children with
ALL carrying t(12;21) from whom diagnostic tumour material
was available, reducing the number of eligible children to 22.
Guthrie cards were available for all 22 children. This investigation
was approved by the Danish Data Protection Agency (1998-1200-
586) and the Scientiﬁc Ethics Committee for the Copenhagen
and Frederiksberg Municipalities (01-94/98).
TEL-AML1 gene sequencing used for primer construction
The nucleotide sequences of the TEL-AML1 and the reciprocal
AML1-TEL fusion gene regions were established by long distance
inverse PCR (LDI-PCR) and sequence determination, as described
in detail elsewhere (Andersen et al, 2001), using as template high
molecular weight chromosomal DNA from leukaemic cells isolated
at time of diagnosis. We successfully identiﬁed the TEL-AML1
breakpoint region for nine out of 22 patients investigated (Ander-
sen et al, 2001). For each of the nine patients, two sets of nested or
semi-nested primers encompassing the fusion region were gener-
ated and used in a nested PCR reaction to amplify the fusion
region directly from the patients’ Guthrie cards (Andersen et al,
2001). As a prelude to Guthrie card analyses, the speciﬁcity of
the patient-speciﬁc primers was tested in analyses of DNA
extracted from corresponding diagnostic tissue samples from the
patients (data not shown).
Guthrie card analysis
Three blood spots, each measuring approximately 1 cm in
diameter, are routinely obtained on the Guthrie card from all
newborn children. Normally, one or two spots are used for screen-
ing purposes, and the residual blood spot(s) are subsequently
stored at 7208C. In the present study, two blood spots were avail-
able in three and one spot in six out of the nine children included.
Genomic DNA was extracted from the Guthrie cards using a
QIAamp DNA Mini Kit (QIAGEN, Ltd, UK), the extraction proce-
dure yielding approximately 120 mL DNA extract per blood spot.
As a general control for the integrity or ampliﬁcability of blood
spot DNA, we performed ‘real time’ PCR on DNA isolated from
randomly selected Guthrie card blood spots of 20 children with
B-precursor ALL without known chromosomal translocations as
well as from 17 healthy children. We used a single-copy gene as
target, i.e. the mannose-binding lectin (MBL) gene, located on
chromosome 10 (PCR primers: 5'-TGGCAGCGTCTT-ACTCA-
GAA–3' and 5'-ATCACTGCA-GGGCAGGTC-3'; TaqMan probe:
5'-6-FAM-CTGTGACCTGTGAGGATGCCCAA –TAMRA-3', stan-
dard set-up and 50 PCR cycles).
For each of the nine children with ALL, a DNA segment cover-
ing the break point region was cloned into pBluescript or l and
used to optimise a nested hot start PCR procedure. A dilution
range of cloned DNA, from 10
73 to 10
712 mg mL
71, was made
in water with salmon sperm (1:10000). Speciﬁc primers for a
nested procedure were identiﬁed to give a ﬁnal amplicon of
190–300 base pairs. The sensitivity of the PCR procedure was
optimised by varying the MgCl2 concentration, the number of
cycles and the annealing temperature. Optimisation was considered
complete when 1–3 copies of the DNA segment could be identi-
ﬁed per reaction. Preliminary dilution experiments with DNA
extracted from artiﬁcially produced Guthrie cards with cloned
DNA did not give results different from experiments with cloned
DNA diluted in water and salmon sperm (data not shown).
Extracted DNA from the nine patients’ Guthrie cards was
analysed by nested PCR using the conditions obtained by the opti-
misation analysis. Analyses were performed on successive 10 mL
DNA extract volumes until a speciﬁc PCR product was obtained
or, alternatively, the entire sample of extracted DNA was analysed.
A no-DNA control was included in each PCR set-up. Any product
of expected size produced by the ﬁlter paper PCR was analysed by
automated DNA sequencing (ABI 310, Applied Biosystems) either
by direct sequencing using an internal primer, or by sequencing
of cloned PCR product, using TOPO-TA-cloning Kit (Invitrogen).
The sequences of the positive samples were veriﬁed by at least two
independent sequencing reactions/clones (Figure 1).
To avoid contamination and prevent false positive results, the
fusion-gene sequencing, Guthrie card DNA extraction and optimi-
sation and the ﬁnal PCR analyses were each carried out at different
institutions.
RESULTS
Twenty-two children with B-precursor ALL and t(12;21) were
included in the study. We were able to identify and sequence
the TEL-AML1 breakpoint region for nine (41%) of the 22
patients. The success rate was affected by sparse/sub-optimal
quality of the diagnostic specimens (primarily low number of
leukaemia cells), resulting in low quality and quantity of DNA
to be used for determination of the individual breakpoint fusion
sequences. The nine patients were between 2 years and 11
months and 6 years and 2 months at leukaemia diagnosis.
Leukaemia clone-speciﬁc fusion gene sequences were demon-
strated in Guthrie card DNA and veriﬁed by sequencing in
three out of nine patients tested, diagnosed with leukaemia at
ages 2 years 11 months, 3 years 4 months, and 5 years 8
months, respectively (Table 1, Figure 1). The fusion-genes were
demonstrated after analysis of 100, 10, and 50 mL DNA extracts,
respectively, in consecutively PCR analyses of 10 mL DNA extract
each. For the Guthrie cards without evidence of fusion genes, the
number of consecutive PCR analyses of 10 mL DNA extract
varied from 11 to 21, depending on the number of blood spots
available, i.e. one or two. There was no correlation between age
of the Guthrie card (data not shown) or tumour burden at diag-
nosis (Table 1) and outcome of screening the patients’ Guthrie
cards.
The MBL gene was ampliﬁed in all 37 randomly selected
Guthrie cards. However, considerable variation in amount of
extracted DNA content was observed, ranging from 100 to 8400
(median 760) genome equivalents per 10 mL DNA extract, the
volume of DNA extract analysed in the patient-speciﬁc transloca-
tion analyses. Age of the Guthrie card did not inﬂuence the
amount of DNA retrieved (data not shown).
DISCUSSION
We demonstrated the TEL-AML1 fusion genes in three out of nine
patients’ Guthrie cards in the present investigation. Our ﬁndings
are compatible with those of Wiemels et al (1999a), who demon-
strated TEL-AML1 fusion genes in six out of nine patients
investigated, and provide further evidence of a prenatal initiation
of t(12;21) B-precursor ALL.
Several factors inﬂuence the ability to demonstrate leukaemia
related genetic markers in DNA extracted from neonatal blood
spots. These include the concentration of ‘pre-leukaemic’ cells at
birth, the number of cells captured on the ﬁlter paper, the state
of preservation of the DNA on the ﬁlter paper, and the sensitivity
of the PCR analyses. Accordingly, while a positive PCR analysis
with a high degree of certainty implies the presence of the investi-
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present study the sensitivity of the PCR reactions makes it most
likely that negative results are due to absence of translocation
speciﬁc DNA, i.e. a very low concentration of translocation bearing
cells, variations in the effectiveness of the DNA extraction proce-
dure or that the DNA is not ampliﬁed sufﬁciently. The large
variation in MBL gene copies recovered from control Guthrie cards
indicates limitations in the DNA quality or the DNA extraction
procedure. In our experience the yield varies considerably, necessi-
tating an optimisation for each Guthrie card. No single parameter,
e.g. the age of the Guthrie card, can be used to predict the effec-
tiveness of extraction. DNA is stable in dried blood spots
(Mccabe et al, 1987) and in our experience, Guthrie cards can be
used as source for DNA at least following storage for 10–15 years
at 7208C. In general all cards retrieved at Statens Serum Institut
are stored at room temperature for 3 to 5 days before freezing.
In order not to reduce the sensitivity of the overall detection of
translocation speciﬁc DNA, we did not use any of the DNA from
the patient-speciﬁc Guthrie card as control. Based on the large
variation in Guthrie card quality and the fact that the number of
TEL-AML1 copies per Guthrie card is Poisson distributed (Larsen
et al, 1996), we decided not to give an estimation of the number of
cells carrying the TEL-AML1 fusion gene at time of birth in case of
a positive Guthrie card.
Including the present investigation, Guthrie card analyses have
now been reported for a total of 51 singletons with various ALL
subtypes in studies employing different types of clonotypic markers
(Gale et al, 1997; Wiemels et al, 1999a; Fasching et al, 2000; Yagi et
al, 2000; Panzer-Grumayer et al, 2002; Taub et al, 2002) (Tables 2
and 3) and 10 singletons with acute myeloid leukaemia (AML)
(Wiemels et al, 2002). Despite sharing a prenatal origin with
ALL, AML represents a different group of diseases with different
natural histories. Accordingly, the Guthrie card results for AML
patients will not be discussed further.
Overall, leukaemia markers have been demonstrated in the
neonatal blood spots in 34 (66%) of the 51 studied children with
ALL. Assuming that all used markers are representative of pre-
leukaemic clones, the likelihood of demonstrating the leukaemia
markers appears to vary with age at leukaemia diagnosis. Accord-
ingly, Guthrie card analyses have been positive in 88% (seven
out of eight) of children aged 0–1 year, in 67% (18 out of 27)
of children aged 2–3 years and in 56% (nine out of 16) of children
aged 4+ years at leukaemia diagnosis. The inverse correlation
between chance of positive PCR result in neonatal Guthrie card
analyses and age at diagnosis (Mann–Whitney P-value=0.04)
may indicate that the burden of cells with the leukaemia clone
characteristics at birth is somehow related to age at leukaemia
diagnosis. Consistent with this speculation, a recent investigation
demonstrated that the number of cells with leukaemia-speciﬁc
IgH gene rearrangements present in individual Guthrie cards was
inversely correlated to age at diagnosis in a series of 12 patients
with B-precursor ALL (Taub et al, 2002).
Unlike the fusion genes resulting from t(12;21) and t(4;11) used
in Guthrie cards analyses, which both appear to be directly
involved in the development of leukaemia (Greaves, 2002), this is
not the case for the other types of clonal markers used to assess
a prenatal origin of leukaemia, TcR and IgH gene rearrangements.
Accordingly, whereas the demonstration of t(12;21) and t(4;11) at
birth implies the presence of leukaemic or leukaemia-predisposed
cells, strictly speaking, no direct inference as to genetic events criti-
cal to leukaemia development can be made from the presence of
leukaemia-speciﬁc TcR and IgH gene rearrangements (Taub et al,
2002). Still, neonatal presence of leukaemia clonal markers have
been reported in similar proportions of patients studied with
t(12;21) or t(4;11) markers and TcR or IgH markers (Tables 2
and 3).
Whereas the wide variety of leukaemia subtypes for which
clonal markers have been demonstrated in neonatal blood spots
might indicate that foetal initiation is a common phenomenon
in childhood leukemia, it is less certain to what extent the
presence of cells with leukaemia-speciﬁc markers in Guthrie cards
reﬂects complete or incomplete leukaemia development. Leukae-
mia diagnosed in infants often display t(4;11), and moreover
the concordance rate for infant leukaemia is seemingly close to
100% in monochorionic monozygotic twins (Gale et al, 1997).
Therefore, the demonstration of cells with t(4;11) fusions genes
in Guthrie cards from ﬁve out of ﬁve children examined develop-
ing leukaemia before or at the age of 2 years indicate a
substantial concentration of t(4;11) carrying cells and conse-
quently that the development of this particular type of
leukaemia may already be fully or nearly completed at birth
(Table 2). In comparison, the later occurrence of t(12;21) B-
precursor ALL, i.e. typically at ages 2–5 years, in combination
with the demonstration of t(12;21) carrying cells in Guthrie cards
in children diagnosed with leukaemia at the age of 5 years in the
setting of a generally less frequent demonstration of leukaemia
clone-speciﬁc t(12;21) translocations in Guthrie cards (Table 2)
suggest a different scenario. Thus, if t(12;21) carrying cells
demonstrated in Guthrie card analysis were fully leukaemic, their
presence would imply a tumour burden of 1:10
5 to 1:10
6, corre-
sponding to the number of nucleated cells captured in a Guthrie
card blood spot (Gale et al, 1997; Taub et al, 2002). However,
MRD studies of childhood ALL have demonstrated that a tumour
burden of 1:10
5 after a few months of therapy is associated with
a high risk of relapse even during therapy (van Dongen et al,
1998), which is hardly compatible with the neonatal presence of
t(12;21) in children diagnosed with leukaemia at ages of nearly
6 years. Instead, t(12;21) carrying cells present at birth most likely
represent clones of leukaemia-predisposed cells which need to
acquire more genetic aberrations to become fully malignant. A
rather low concordance of childhood ALL in monozygotic twins
would be consistent with this hypothesis (Ford et al, 1998), as
would the demonstration of identical TEL-AML1 fusion genes
in a set of monozygotic twins diagnosed with t(12;21) B-precur-
sor ALL at ages 9 and 14 years (Wiemels et al, 1999b) as well as
the simultaneous existence of identical TEL-AML1 fusion genes
and non-identical deletions of the TEL gene, also believed to play
a role in leukaemia development, in a pair of monozygotic twins
concordant for t(12;21) positive ALL (Maia et al, 2001). In addi-
tion, a recent published paper indicated that t(12;21)-positive cells
may be demonstrated in as many as one in 100 newborns, i.e.
100 times the proportion of children that will develop overt
t(12;21)-positive ALL before the age of 15 years (Mori et al,
2002).
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Table 1 Results of screening Guthrie cards of nine patients with B-pre-
cursor acute lymphoblastic leukaemia for the presence of TEL-AML1 break
point regions
White blood cell count
Patient Sex Age at diagnosis at diagnosis (10
9 L
71) PCR results
1 M 2 Y 11 M 32.8 Positive
2 M 3 Y 3 M 9.2 Negative
3 M 3 Y 4 M 43.3 Positive
4 M 3 Y 5 M 11 Negative
5 F 3 Y 11 M 163 Negative
6 M 4 Y 2 M 6 Negative
7 M 5 Y 6 M 18 Negative
8 M 5Y8M 5 Positive
9 F 6 Y 2 M 18 Negative
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TEL-1 TEL-2
AML-2
AML-1
TEL-1 TEL-2
AML-2
AML-1
Patient 8
Patient 1 Patient 3
B
M
GC            NTC GC         NTC GC
Patient 1 Patient 3 Patient 8
A
AML-2
AML-1
TEL-1
TEL-2
NTC
Figure 1 (A) Demonstrates the three translocation positive samples run on a 3% agarose gel electrophoresis. M: Molecular size marker pBR 327/Hae III.
GC: DNA extract from the patient’s Guthrie card. NTC: Non-template control. Sizes of the PCR products were: (Patient 1) 242/190 bp, (Patient 3)
183 bp and (Patient 8) 166 bp. The two fragment sizes in Patient 1, is due to inefﬁcient nesting of one of the second round PCR primers. The identities
were veriﬁed by direct sequence analysis. (B) The three patients individual chromosomal fusion regions are demonstrated. The arrows indicate the PCR
primers used in the nested PCR reactions for the detection of the fusion gene (primer 1 followed by primer 2). The vertical line/box shows the site of fusion
gene and the box demonstrates the base pairs introduced by the fusion gene event.
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Table 3 Results of screening of Guthrie cards for clone-speciﬁc immune gene rearrangements regions in 26 singletons
with B-precursor acute lymphoblastic leukaemia and two singletons with T-cell acute lymphoblastic leukaemia; by age at
diagnosis
Age at Clonotypic
Patients diagnosis
aChromosomal aberration PCR result marker used Reference
1 14 D t(4:11:15) Positive IgH/TCRD Yagi et al, 2000
2 2 M t(4;11) Positive IgH Yagi et al, 2000
3 1 Y 6 M t(11;12) Negative IgH Yagi et al, 2000
4 1 Y 6 M Hyperdiploidy (DNA index 1.13) Positive IgH Taub et al, 2002
5 2 Y Normal Positive IgH/TCRD Yagi et al, 2000
6 2 Y Normal Negative IgH/TCRD Yagi et al, 2000
7 2 Y 1 M Normal Positive IgH Taub et al, 2002
82 Y 1 M
b Normal Positive IgH/TCRG Fasching et al, 2000
92 Y 2 M
b Normal Positive IgH/TCRG Fasching et al, 2000
10 2 Y 3 M Hyperdiploidy (450) Positive IgH/TCRD Yagi et al, 2000
11 2 Y 3 M Hyperdiploidy (450) Positive IgH Taub et al, 2002
12 2 Y 6 M Hyperdiploidy (47) Negative IgH Taub et al, 2002
13 2 Y 7 M Hyperdiploidy (450) Positive IgH Panzer-Grumayer et al, 2002
14 2 Y 9 M Hyperdiploidy (48) Positive IgH Taub et al, 2002
15 2 Y 10 M Hyperdiploidy (450) Positive IgH Taub et al, 2002
16 2 Y 11 M t(12;21) Positive IgH Taub et al, 2002
17 3 Y 6 M Hyperdiploidy (450) Positive IgH Taub et al, 2002
18 3 Y 10 M Normal Negative IgH Taub et al, 2002
19 4 Y Normal Negative IgH Taub et al, 2002
20 4 Y Hyperdiploidy (47) Negative IgH Taub et al, 2002
21 4 Y 8 M Normal Positive IgH Fasching et al, 2000
22 5 Y Hyperdiploidy (DNA index 1.16) Positive IgH Taub et al, 2002
23 8 Y Pseudodiploidy (del(6)) Positive IgH Taub et al, 2002
24 9 Y Hyperdiploidy Positive IgH Taub et al, 2002
25 9 Y (Down syndrome) Negative IgH Taub et al, 2002
26 9 Y Normal Negative IgH/TCRD Yagi et al, 2000
27 10 Y Hyperdiploidy (47) and t(4;11) Positive IgH Taub et al, 2002
28 13 Y t(1;19) Positive IgH Taub et al, 2002
aThe chromosomal aberrations are presented as given by the speciﬁc papers.
bThe two patients with T-cell acute lymphoblastic
leukaemia.
Table 2 Results of screening of Guthrie cards for clone-speciﬁc fusion gene regions in 23 singletons
with B-precursor acute lymphoblastic leukaemia; by age at diagnosis
Age at Clonotypic marker used
Patients diagnosis on Guthrie card PCR result Reference
1 5 M MLL-AF4 fusion gene Positive Gale et al, 1997
2 6 M MLL-AF4 fusion gene Positive Gale et al, 1997
3 6 M MLL-AF4 fusion gene, IgH rearrangement Positive Fasching et al, 2000
4 1 Y MLL-AF4 fusion gene, IgH rearrangement Positive Fasching et al, 2000
5 2 Y MLL-AF4 fusion gene Positive Gale et al, 1997
6 2 Y 1 M TEL-AML1 fusion gene Positive Wiemels et al, 1999a
7 2 Y 10 M TEL-AML1 fusion gene Positive Wiemels et al, 1999a
8 2 Y 1 M TEL-AML1 fusion gene Positive
a
9 3 Y 3 M TEL-AML1 fusion gene Negative
a
10 3 Y 3 M TEL-AML1 fusion gene Positive Wiemels et al, 1999a
11 3 Y 4 M TEL-AML1 fusion gene Positive
a
12 3 Y 4 M TEL-AML1 fusion gene Negative Wiemels et al, 1999a
13 3 Y 5 M TEL-AML1 fusion gene Negative Wiemels et al, 1999a
14 3 Y 5 M TEL-AML1 fusion gene Negative
a
15 3 Y 6 M TEL-AML1 fusion gene Positive Wiemels et al, 1999a
16 3 Y 11 M TEL-AML1 fusion gene Negative
a
17 3 Y 11 M TEL-AML1 fusion gene Negative Wiemels et al, 1999a
18 4 Y 2 M TEL-AML1 fusion gene Negative
a
19 4 Y 3 M TEL-AML1 fusion gene Positive Wiemels et al, 1999a
20 5 Y 1 M TEL-AML1 fusion gene Positive Wiemels et al, 1999a
21 5 Y 6 M TEL-AML1 fusion gene Negative
a
22 5 Y 8 M TEL-AML1 fusion gene Positive
a
23 6 Y 2 M TEL-AML1 fusion gene Negative
a
aResults of present investigation.
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British Journal of Cancer (2002) 87(9), 994–999 ã 2002 Cancer Research UKIn conclusion, we demonstrated the presence of cells carrying
leukaemia-speciﬁc TEL-AML1 fusion genes in the Guthrie cards
of three patients diagnosed with B-precursor ALL at ages up to
nearly 6 years. Our ﬁndings provide further evidence that the
development of this type of leukaemia may be initiated in utero
and are consistent with the hypothesis that ALL in childhood
develop as a multiple hit process involving both pre- and postnatal
genetic events.
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